Targeting the androgen receptor signaling axis to reduce testosterone levels in prostate cancer: how low should we go?

Almost three-quarters of a century have elapsed since the Nobel Prize–winning discovery by Huggins and Hodges of the androgen dependence of prostate cancer, and blockade of the androgen receptor (AR)-signaling pathway remains a cornerstone of treatment.[1] As reviewed by Dr. Bastos and his colleagues in this issue of ONCOLOGY, it is now well established that castration-resistant disease can be effectively treated using newer AR-targeting agents such as abiraterone and enzalutamide.[2]